Stock VAL VALIRX PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials ValiRx plc

Equities

VAL

GB00BLH13C52

Biotechnology & Medical Research

Market Closed - London S.E.
Other stock markets
 11:35:00 2024-05-07 am EDT 		5-day change 1st Jan Change
3.3 GBX +1.54% Intraday chart for ValiRx plc 0.00% -44.07%
Apr. 24 Valirx plc Reiterates Earnings Guidance for the Year 2024 CI
Apr. 22 Valirx plc Announces Directorate Changes CI

Valuation

Fiscal Period: December 2018 2020 2021 2022 2023
Capitalization 1 4.936 12.65 23.58 9.107 4.368
Enterprise Value (EV) 1 4.877 12.65 22.99 7.969 2.568
P/E ratio -0.88 x -0.05 x - - -0.02 x
Yield - - - - -
Capitalization / Revenue - - - - -
EV / Revenue - - - - -
EV / EBITDA -1.31 x - - -4.33 x -1.27 x
EV / FCF -1.33 x - - - -1.22 x
FCF Yield -75.4% - - - -81.8%
Price to Book - - - - 0.01 x
Nbr of stocks (in thousands) 4,786 64,882 65,049 65,049 132,349
Reference price 2 1.031 0.1950 0.3625 0.1400 0.0330
Announcement Date 5/29/19 4/27/21 6/7/22 6/5/23 -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2020 2021 2022 2023
Net sales 1 - - - - -
EBITDA 1 -3.723 - - -1.842 -2.014
EBIT 1 -3.866 - -1.678 -2.593 -2.321
Operating Margin - - - - -
Earnings before Tax (EBT) 1 -4.829 - - - -2.322
Net income 1 -4.299 -1.443 - - -2.132
Net margin - - - - -
EPS 2 -1.175 -3.810 - - -2.100
Free Cash Flow 1 -3.678 - - - -2.1
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 5/29/19 4/27/21 6/7/22 6/5/23 -
1GBP in Million2GBP
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2020 2021 2022 2023
Net Debt 1 - - - - -
Net Cash position 1 0.06 - 0.59 1.14 1.8
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 1 -3.68 - - - -2.1
ROE (net income / shareholders' equity) - - - - -
ROA (Net income/ Total Assets) - - - - -
Assets 1 - - - - -
Book Value Per Share 2 - - - - 4.400
Cash Flow per Share - - - - -
Capex 1 0.32 - - - 0.31
Capex / Sales - - - - -
Announcement Date 5/29/19 4/27/21 6/7/22 6/5/23 -
1GBP in Million2GBP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VALIRX PLC Stock ValiRx plc
-44.07% 5.41M
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.44% 106B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+0.82% 104B
ARGENX SE Stock argenx SE
+6.72% 23.25B
BIONTECH SE Stock BioNTech SE
-13.89% 22.5B
GENMAB A/S Stock Genmab A/S
-6.64% 18.7B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.26% 17.95B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.98% 16.99B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+8.67% 14.26B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+41.08% 12.76B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VAL Stock
  4. Financials ValiRx plc
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW